This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Chairman’s Overview/The Place of Reboxetine in Antidepressant Therapy

Stuart A. Montgomery, M.D.

Published: July 1, 1998

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

A wide range of antidepressants is now availableincluding the tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), reversiblemonoamine oxidase-A inhibitors (RIMAs), serotonin selectivereuptake inhibitors (SSRIs), serotonin and norepinephrinereuptake inhibitors (SNRIs), and atypical antidepressantssuch as mirtazapine and nefazodone. However,clinicians still face a number of problems when selectingthe most appropriate antidepressant for a given patient.TCAs are effective in a wide range of patients, but they dohave significant drawbacks in terms of their tolerabilityand safety in overdose, reflecting actions at sites otherthan those involved in the antidepressant effect.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: